HIV proteinase inhibitors: do they really work against Candida in a clinical setting?
Cassone
Antonio
A
Dept of Bacteriology and Medical Mycology, Istituto Superiore di Sanità, Rome, Italy. cassone@iss.it
Cauda
Roberto
R
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002175:Candida / Q000187:drug effects* / Q000201:enzymology; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D015195:Drug Design; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012463:Saliva / Q000201:enzymology
D017320:HIV Protease Inhibitors; D011480:Protease Inhibitors; D016282:Aspartic Acid Endopeptidases